key: cord-0745244-gj833e47
authors: Bendjelid, Karim; Giraud, Raphael; Düring, Stephan Von
title: Treating hypoxemic COVID-19 “ARDS” patients with almitrine: The earlier the better?
date: 2020-07-09
journal: Anaesth Crit Care Pain Med
DOI: 10.1016/j.accpm.2020.07.003
sha: 54849c6a6fc17e87000bdddd2fb76605b3141105
doc_id: 745244
cord_uid: gj833e47

nan

COVID-19 viral pneumonia (pneumonitis) is an acute respiratory illness associated with a new dropletborne coronavirus (SARS-CoV-2). To this day, the pandemic has resulted in over 9 million infections worldwide with over 470,000 deaths, and is associated with a profound disruption of the world's health systems and economy. Surprisingly, the majority of infected patients exhibit good thoraco-pulmonary compliance with preserved lung mechanics following intubation and mechanical ventilation (MV) [1, 2] . Nevertheless, the dominant respiratory feature is profound and disproportionate hypoxemia [1].

In a recent editorial published in the JAMA, Marini and Gattinoni argue that deep sedation and MV should be implemented early on in order to prevent COVID-19 patients from generating spontaneous inspiratory efforts [3] . The authors state that in the early phase of lung infection, the high transpulmonary pressures associated with spontaneous vigorous inspiratory efforts may provoke selfinduced lung injuries (P-SILI) [3] . Even if we agree with this present opinion, it is difficult to make the decision to intubate and paralyse not very symptomatic -but profoundly hypoxemic -patients when the main cause of this condition is a severe intrapulmonary oxygen shunt [2, 4] . Indeed, it appears that the present SARS-CoV-2 pneumonitis induces a significant intrapulmonary capillary shunt resulting from a loss of hypoxic pulmonary vasoconstriction (HPV, Euler-Liljestrand mechanism) [4] [5] [6] . When recalcitrant hypoxemia is present, specific non-ventilatory strategies like body positioning (prone and anti-Trendelenburg) and pharmacological treatments, especially intravenous (IV) almitrinebismesylate, may be of interest [4] .

Almitrine is a scientifically recognised drug that enhances HPV by a vasoconstrictor effect specific to pulmonary arteries via a calcium mediated action [7] . In hypoxemic patients with acute respiratory distress syndrome (ARDS), this medication has been used with success [8, 9] . In this regard, in this issue of Anaesthesia Critical Care Pain Medicine, the reader will find two interesting articles examining different, but converging, prospects of IV almitrine administration on ventilation-perfusion inequalities in COVID-19 ARDS patients. Both authors hypothesised that IV almitrine may restore some blood oxygenation, even partially, when associated with postural manoeuvres and/or nitric oxide (NO) inhalation. What do these two studies add to what is already known on this topic? First, the benefit of a combination of NO inhalation and almitrine on PaO2/FiO2 ratios is more important in the early exudative phase than in the proliferative phase of severe classical ARDS [8, 9, 12] . This same timeframe can be found in COVID-19 ARDS and can be explained by the fact that, in the early phase, lung injury probably results from the gas side of the alveolus (alveolar oedema). The evolution of the COVID-19 (late phase) appears to include an important endothelial insult with histological evidence of endothelial dysfunction [13] that mandates an additional vascular and rheological approach [3] .

Second, a combination of gravitational and pharmacological intervention (prone positioning and J o u r n a l P r e -p r o o f almitrine) improve PaO2/FiO2 ratios of severe ARDS patients, principally in the early phase of ARDS [14] . The gravitational posture potentiates HPV induced by an almitrine infusion, which acts to divert pulmonary blood flow away from poorly ventilated alveoli toward well-ventilated areas. However, regrettably in the second investigation [11] , there was insufficient echocardiographic assessment needed to exclude a patent foramen ovale. Indeed, the haemodynamic effects of almitrine on pulmonary arterial pressure and right ventricular pressures [15] may induce an intra-cardiac shunt that offsets and abolishes the benefit of the drug on blood oxygenation. What can be learned from the present studies? Reading these articles is stimulating to intensivists and physiologists who are currently facing the unprecedented challenge of treating and ventilating COVID-19 ARDS patients. As already stated above, several features of SARS-CoV-2 pneumonitis distinguish it from typical ARDS. First, patients often display a silent hypoxemia with very few clinical symptoms (dyspnoea) despite low PaO2/FiO2 ratios [4] . Such a condition is probably related to an impairment of the carotid body sensors, which physiologically senses hypoxemia and increases the respiratory drive.

Second, the severe hypoxemia is mainly due to a large intrapulmonary capillary oxygen shunt linked to loss of HPV. At this point, we turn the question over to the reader: how can we use physiology to treat a failure of the body's homeostatic O2-sensing system, which includes both the pulmonary circulation and the carotid body sensors [4] ? The present question is crucial since the surest way to increase COVID-19 mortality is the liberal use of intubation and MV [1]. Indeed, although frequently life-saving during threatening hypoxemia, MV is also associated with various complications, some of them life-threatening in and of themselves [4] . In this regard, the key factor that could make almitrine administration of great importance in COVID-19 patients is its ability to avoid intubation and MV [17] .

Finally, if we revisit recent results in the existing literature, we may say that administration of IV almitrine in the early phase of lung injury and ARDS may be associated with an improvement in arterial blood oxygenation in COVID-19 ARDS patients. As previously stated in another editorial, the proposed pharmacological treatment seems justified as long as its aim is to prevent intubation and MV, or improve MV weaning, without further deterioration of the patient's dangerous state [4] .

Basing Respiratory Management of COVID-19 on Physiological Principles. American journal of respiratory and critical care medicine

COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome. American journal of respiratory and critical care medicine

Management of COVID-19 Respiratory Distress

Treating hypoxemic patients with SARS-COV-2 pneumonia: Back to applied physiology

Physiology in medicine: importance of hypoxic pulmonary vasoconstriction in maintaining arterial oxygenation during acute respiratory failure

Role of hypoxic pulmonary vasoconstriction in pulmonary gas exchange and blood flow distribution. 2. Pathophysiology. Intensive care medicine

Hypoxic pulmonary vasoconstriction: physiology and anesthetic implications

Inhaled nitric oxide and vasoconstrictors in acute respiratory distress syndrome. American journal of respiratory and critical care medicine

Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome. The NO Almitrine Study Group. American journal of respiratory and critical care medicine

Almitrine as a non-ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients

Effect of almitrine bismesylate and inhaled nitric oxide on oxygenation in COVID-19 acute respiratory distress syndrome

Almitrine and NO in acute respiratory distress syndrome: two pieces of the same puzzle?

The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection

Combined nitric oxide inhalation, prone positioning and almitrine infusion improve oxygenation in severe ARDS

Right ventricular response to high-dose almitrine infusion in patients with severe hypoxemia related to acute respiratory distress syndrome

Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome

Intubation and mechanical ventilation avoided by using almitrine bismesylate in an acute hypoxemic pneumonia